Neumora Therapeutics, Common Stock Retained Earnings
| NMRA Stock | 1.56 0.01 0.65% |
Neumora Therapeutics, Common fundamentals help investors to digest information that contributes to Neumora Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Neumora Stock. The fundamental analysis module provides a way to measure Neumora Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neumora Therapeutics, stock.
Neumora |
Neumora Therapeutics, Common Company Retained Earnings Analysis
Neumora Therapeutics,'s Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Neumora Therapeutics, Retained Earnings | (703.43 M) |
Most of Neumora Therapeutics,'s fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neumora Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Neumora Therapeutics, Common has a Retained Earnings of (703.43 Million). This is 175.53% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is 107.54% higher than that of the company.
Neumora Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neumora Therapeutics,'s direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neumora Therapeutics, could also be used in its relative valuation, which is a method of valuing Neumora Therapeutics, by comparing valuation metrics of similar companies.Neumora Therapeutics, is currently under evaluation in retained earnings category among its peers.
Neumora Fundamentals
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | (86.53 M) | ||||
| Shares Outstanding | 161.56 M | ||||
| Shares Owned By Insiders | 27.60 % | ||||
| Shares Owned By Institutions | 72.13 % | ||||
| Number Of Shares Shorted | 11.2 M | ||||
| Price To Book | 0.78 X | ||||
| EBITDA | (187.53 M) | ||||
| Net Income | (235.93 M) | ||||
| Total Debt | 5.23 M | ||||
| Book Value Per Share | 2.00 X | ||||
| Cash Flow From Operations | (163.28 M) | ||||
| Short Ratio | 4.59 X | ||||
| Earnings Per Share | (1.20) X | ||||
| Target Price | 11.77 | ||||
| Number Of Employees | 109 | ||||
| Market Capitalization | 252.04 M | ||||
| Total Asset | 496.19 M | ||||
| Retained Earnings | (703.43 M) | ||||
| Working Capital | 453.17 M | ||||
| Net Asset | 496.19 M |
About Neumora Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neumora Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neumora Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neumora Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neumora Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neumora Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neumora Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neumora Therapeutics, Common Stock:Check out Neumora Therapeutics, Piotroski F Score and Neumora Therapeutics, Altman Z Score analysis. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.